Phase 2 Study of Personalized r-ATG Dosing to Improve Survival through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing ex vivo CD34-Selected Allogeneic HCT (PRAISE IR)
What's the purpose of the trial?
The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects. Participants in this study will be children and adults who have acute leukemia or myelodysplastic syndrome (MDS), and will receive a standard conditioning regimen to prepare the body for an allogeneic hematopoietic cell transplant (allo-HCT). The conditioning regimen will include r-ATG, one of two combinations of chemotherapy, and possibly total body irradiation (TBI).
There is one center participating in this trial. Enter a location below to view the distance.
Learn more about the experimental treatments being evaluated in this clinical trial.
- Thiotepa is an antineoplastic chemotherapy agent that is used to treat several different kinds of cancer.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Radiation is used to fight may types of cancer including multiple myeloma. Cancer cells multiply faster than normal cells in the body. Radiation is most harmful to quickly growing cells, so radiation therapy damanges cancer cells more than normal cells. This stops cancer cells from growing and dividing and leads to cell death.
- Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body.
- Melphalan is a chemotherapy medication used in the treatment of multiple myeloma.
- Fludarabine is a chemotherapy agent used in the treatment of cancer.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!